D.I. Trukhan
Abstract
The main target of the new coronavirus infection (COVID19), spread by the SARS-CoV-2 virus, is the respiratory system. SARS-CoV-2 infection can cause kidney damage, and severe renal dysfunction is more common in patients with chronic comorbid/multimorbid disease, especially in patients with chronic kidney disease. A search was made for literature on the association of major diseases (pathological conditions) of the kidneys and urinary tract with the new coronavirus infection COVID-19 in electronic search engines PubMed, Scopus, eLIBRARY. The found literary sources indicate that the new coronavirus infection COVID-19 certainly has a specific effect on the urinary system in general, and in particular, on certain diseases of the kidneys and urinary tract.
Key words: new coronavirus infection (COVID-19), acute kidney injury, acute renal failure, chronic kidney disease, chronic renal failure, cystitis, lower urinary tract symptoms, pyelonephritis, urolithiasis, glomerulonephritis, drug nephrotoxicity.
Key words: new coronavirus infection (COVID-19), acute kidney injury, acute renal failure, chronic kidney disease, chronic renal failure, cystitis, lower urinary tract symptoms, pyelonephritis, urolithiasis, glomerulonephritis, drug nephrotoxicity.
About the Author
D.I. Trukhan 11 Omsk State Medical University, Omsk, Russia
References
1. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Минздрава России (15-я версия от 22.02.2022). М., 2022. https://static-0.minzdrav.gov.ru/system/attachments/attaches/ 000/059/392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf
[Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii Minzdrava Rossii (15-ia versiia ot 22.02.2022). Moscow, 2022. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/VMR_COVID-19_V15.pdf (in Russian).]
2. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9 (1):727–32. DOI: 10.1080/22221751.2020.1746199
3. Zou X, Chen K, Zou J et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020; 14 (2): 185–92. DOI: 10.1007/ s11684-020-0754-0
4. Wang M, Xiong H, Chen H et al. Renal Injury by SARS-CoV-2 Infection: A Systematic Review. Kidney Dis (Basel). 2021 Mar; 7 (2): 100–10. DOI: 10.1159/000512683
5. Томилина Н.А., Фролова Н.Ф., Артюхина Л.Ю. и др. COVID-19: связь с патологией почек. Обзор литературы. Нефрология и диализ. 2021; 2: 147–59. https://www.elibrary.ru/item.asp?id= 46215426
[Tomilina N.A., Frolova N.F., Artiukhina L.Iu. et al. COVID-19: sviaz' s patologiei pochek. Obzor literatury. Nefrologiia i dializ. 2021; 2: 147–59. https://www.elibrary.ru/item.asp?id=46215426 (in Rus-sian).]
6. Павлов В.Н., Тарасенко А.И., Папоян А.О. и др. Острое повреждение почек в патогенезе коронавирусной инфекции. Урология. 2021; 2: 116–9. DOI: 10.18565/urology.2021.2.116-119
[Pavlov V.N., Tarasenko A.I., Papoian A.O. et al. Ostroe povrezhdenie pochek v patogeneze koronavirusnoi infektsii. Urologiia. 2021; 2: 116–9. DOI: 10.18565/urology.2021.2.116-119 (in Russian).]
7. Демяшкин Г.А., Мингазов А.М., Каприна Е.А. и др. Молекулярно-генетические изменения ткани почек пациентов с COVID-19. Исследования и практика в медицине. 2021; 8 (3): 45–51. DOI: 10.17709/2410-1893-2021-8-3-4
[Demiashkin G.A., Mingazov A.M., Kaprina E.A. et al. Molekuliarno-geneticheskie izmeneniia tkani pochek patsientov s COVID-19. Issledovaniia i praktika v meditsine. 2021; 8 (3): 45–51. DOI: 10.17709/2410-1893-2021-8-3-4 (in Russian).]
8. Ouyang L, Gong Y, Zhu Y, Gong J. Association of acute kidney injury with the severity and mortality of SARS-CoV-2 infection: A meta-analysis. Am J Emerg Med 2021; 43: 149–57. DOI: 10.1016/j.ajem.2020 08.089
9. Острое повреждение почек (ОПП). Клинические рекомендации. М., 2020. https://rusnephrology.org/wp-content/uploads/2020/12/ AKI_final.pdf
[Ostroe povrezhdenie pochek (OPP). Klinicheskie rekomendatsii. Moscow, 2020. https://rusnephrology.org/wp-content/uploads/ 2020/12/AKI_final.pdf (in Russian).]
10. Pecly IMD, Azevedo RB, Muxfeldt ES et al. A review of Covid-19 and acute kidney injury: from pathophysiology to clinical results. J Bras Nefrol 2021; 43 (4): 551–71. DOI: 10.1590/2175-8239-JBN-2020-0204
11. Yang XH, Sun RH, Chen DC. Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored. Zhonghua Yi Xue Za Zhi 2020; 100 (16): 1205–8. DOI: 10.3760/cma.j.cn112137-20200229-00520
12. Ng JH, Bijol V, Sparks MA et al. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis 2020; 27 (5): 365–76. DOI: 10.1053/j.ackd.2020.09.003
13. Menon T, Sharma R, Kataria S et al. The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. Cureus 2021; 13 (3): e13894. DOI: 10.7759/cureus.13894
14. Chan KW, Yu KY, Lee PW et al. Global REnal Involvement of CORonavirus Disease 2019 (RECORD): A Systematic Review and Meta-Analysis of Incidence, Risk Factors, and Clinical Outcomes. Front Med (Lausanne) 2021; 8: 678200. DOI: 10.3389/fmed.2021.678200
15. Oliveira CB, Lima CAD, Vajgel G et al. High burden of acute kidney injury in COVID-19 pandemic: systematic review and meta-analysis. J Clin Pathol 2021; 74 (12): 796–803. DOI: 10.1136/jclinpath-2020-207023
16. Alenezi FK, Almeshari MA, Mahida R et al. Incidence and risk factors of acute kidney injury in COVID-19 patients with and without acute respiratory distress syndrome (ARDS) during the first wave of COVID-19: a systematic review and Meta-Analysis. Ren Fail 2021; 43 (1): 1621–33. DOI: 10.1080/0886022X.2021.2011747
17. Raina R, Mahajan ZA, Vasistha P et al. Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review. Blood Purif 2021: 1–14. DOI: 10.1159/000514940
18. Santos RPD, Lordani TVA, Peres LAB, Carvalho ARDS. Occurrence of acute kidney injury in adult patients hospitalized with COVID-19: A systematic review and meta-analysis. Nefrologia (Engl Ed) 2021. DOI: 10.1016/j.nefro.2021.09.002
19. Cai X, Wu G, Zhang J, Yang L. Risk Factors for Acute Kidney Injury in Adult Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021; 8: 719472. DOI: 10.3389/fmed.2021.719472
20. Чеботарева Н.В., Бернс С.А., Мясников А.Л. и др. Частота, факторы риска и прогностическое значение острого повреждения почек у госпитализированных больных c COVID-19: ретроспективное когортное исследование. Клиническая фармакология и терапия. 2021; 1: 30–5. DOI: 10.32756/0869-5490-2021-1-30-35
[Chebotareva N.V., Berns S.A., Miasnikov A.L. et al. Chastota, faktory riska i prognosticheskoe znachenie ostrogo povrezhdeniia pochek u gospitalizirovannykh bol'nykh c COVID-19: retrospektivnoe kogortnoe issledovanie. Klinicheskaia farmakologiia i terapiia. 2021; 1: 30–5. DOI: 10.32756/0869-5490-2021-1-30-35 (in Russian).]
21. Chan VW, Chiu PK, Yee CH et al. A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions. World J Urol 2021; 39 (9): 3127–38. DOI: 10.1007/s00345-020-03246-4
22. Громова Г.Г., Верижникова Л.Н., Жбанова Н.В. и др. Повреждение почек при новой коронавирусной инфекции COVID-19. Клиническая нефрология. 2021; 3: 17–22. DOI: 10.18565/nephrology.2021.3.17-22
[Gromova G.G., Verizhnikova L.N., Zhbanova N.V. et al. Povrezhdenie pochek pri novoi koronavirusnoi infektsii COVID-19. Klinicheskaia nefrologiia. 2021; 3: 17–22. DOI: 10.18565/nephrology.2021.3.17-22 (in Russian).]
23. Cai R, Zhang J, Zhu Y et al. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. Int Urol Nephrol 2021; 53 (8): 1623–9. DOI: 10.1007/s11255-020-02740-3
24. Menon T, Gandhi SAQ, Tariq W et al. Impact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis. Cureus 2021; 13 (4): e14279. DOI: 10.7759/cureus.14279
25. Lin YC, Lai TS, Lin SL et al. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021; 12: 2040622321998860. DOI: 10.1177/2040622321998860
26. Chung EYM, Palmer SC, Natale P et al. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis 2021; 78 (6): 804–15. DOI: 10.1053/j.ajkd. 2021.07.003
27. Singh J, Malik P, Patel N et al. Kidney disease and COVID-19 disease severity-systematic review and meta-analysis. Clin Exp Med 2022; 22 (1): 125–35. DOI: 10.1007/s10238-021-00715-x
28. Nopsopon T, Kittrakulrat J, Takkavatakarn K et al. Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis. PLoS Negl Trop Dis 2021; 15 (6): e0009156. DOI: 10.1371/journal.pntd.0009156
29. Wang F, Ao G, Wang Y et al. Risk factors for mortality in hemodialysis patients with COVID-19: a systematic review and meta-analysis. Ren Fail 2021; 43 (1): 1394–407. DOI: 10.1080/0886022X. 2021.1986408
30. Сивков А.В., Корякин А.В., Синягин А.А. и др. Мочеполовая система и COVID-19: некоторые аспекты. Экспериментальная и клиническая урология. 2020; 2: 18–23. DOI: 10.29188/2222-8543-2020-12-2-18-23
[Sivkov A.V., Koriakin A.V., Siniagin A.A. et al. Mochepolovaia sistema i COVID-19: nekotorye aspekty. Eksperimental'naia i klinicheskaia urologiia. 2020; 2: 18–23. DOI: 10.29188/2222-8543-2020-12-2-18-23 (in Russian).]
31. Heldwein FL, Loeb S, Wroclawski ML et al. A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic. Eur Urol Focus 2020; 6 (5): 1070–85. DOI: 10.1016/j.euf.2020.05.020
32. Лаухтина Е.А., Шпикина А.Д., Тараткин М.С. и др. Обзор рекомендаций европейской ассоциации урологов по ведению урологических пациентов в период пандемии COVID-19. Вопросы урологии и андрологии. 2020; 1: 52–9. DOI: 10.20953/2307-6631-2020-1-52-59
[Laukhtina E.A., Shpikina A.D., Taratkin M.S. et al. Obzor rekomendatsii evropeiskoi assotsiatsii urologov po vedeniiu urologicheskikh patsientov v period pandemii COVID-19. Voprosy urologii i andrologii. 2020; 1: 52–9. DOI: 10.20953/2307-6631-2020-1-52-59 (in Russian).]
33. Малхасян В.А., Касян Г.Р., Ходырева Л.А. и др. Оказание стационарной помощи пациентам урологического профиля в условиях пандемии коронавирусной инфекции COVID-19. Экспериментальная и клиническая урология. 2020; 1: 4–11. DOI: 10.29188/2222-8543-2020-12-1-4-11
[Malkhasian V.A., Kasian G.R., Khodyreva L.A. et al. Okazanie statsionarnoi pomoshchi patsientam urologicheskogo profilia v usloviiakh pandemii koronavirusnoi infektsii COVID-19. Eksperimental'naia i klinicheskaia urologiia. 2020; 1: 4–11. DOI: 10.29188/2222-8543-2020-12-1-4-11 (in Russian).]
34. Mumm JN, Osterman A, Ruzicka M et al. Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis? Eur Urol 2020; 78 (4): 624–8. DOI: 10.1016/j.eururo.2020.05.013
35. Lamb LE, Dhar N, Timar R et al. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Med Hypotheses 2020; 145: 110375. DOI: 10.1016/j.mehy. 2020.110375
36. Dhar N, Dhar S, Timar R et al. De Novo Urinary Symptoms Associated With COVID-19: COVID-19-Associated Cystitis. J Clin Med Res 2020; 12 (10): 681–2. DOI: 10.14740/jocmr4294
37. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных синдромов и симптомов при заболеваниях почек и мочевых путей. М.: Практическая медицина, 2019. https://www. elibrary.ru/item.asp?id=47503998
[Trukhan D.I., Filimonov S.N. Differentsial'nyi diagnoz osnovnykh sindromov i simptomov pri zabolevaniiakh pochek i mochevykh putei. Moscow: Prakticheskaia meditsina, 2019. https://www.elibrary. ru/item.asp?id=47503998 (in Russian).]
38. Трухан Д.И., Юренев Г.Л., Макушин Д.Г., Чусова Н.А. Симптомы нижних мочевых путей: дифференциальный диагноз на этапе оказания первичной медико-санитарной помощи. Справочник поликлинического врача. 2019; 3: 23–8. https://www.elibrary.ru/ item.asp?id=41351801
[Trukhan D.I., Iurenev G.L., Makushin D.G., Chusova N.A. Simptomy nizhnikh mochevykh putei: differentsial'nyi diagnoz na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi. Spravochnik poliklinicheskogo vracha. 2019; 3: 23–8. https://www.elibrary.ru/ item.asp?id=41351801 (in Russian).]
39. Kaya Y, Kaya C, Kartal T et al. Could LUTS be early symptoms of COVID-19. Int J Clin Pract 2021; 75 (3): e13850. DOI: 10.1111/ ijcp.13850
40. Bernikov AN, Kupriyanov AA, Stroganov RV et al. Lower urinary tract symptoms and COVID-19. Urologiia 2021; 5: 78–83. https://pubmed.ncbi.nlm.nih.gov/35165599/
41. Lamb LE, Timar R, Wills M et al. Long COVID and COVID-19-associated cystitis (CAC). Int Urol Nephrol 2022; 54 (1): 17–21. DOI: 10.1007/s11255-021-03030-2
42. Pourfridoni M, Pajokh M, Seyedi F. Bladder and bowel incontinence in COVID-19. J Med Virol 2021; 93 (5): 2609–10. DOI: 10.1002/ jmv.26849
43. Araujo MP, Brito LGO, Pochini AC et al. Prevalence of Urinary Incontinence in CrossFit Practitioners before and during the COVID-19 Quarantine and its Relationship with Training Level: An Observational Study. Rev Bras Ginecol Obstet 2021; 43 (11): 847–52. DOI: 10.1055/s-0041-1739463
44. Борисов В.В. Опасности COVID-нейроинфекции и ее урологических осложнений, возможные пути преодоления (клиническая лекция). Клинический разбор в общей медицине. 2021; 6: 35–41. DOI: 10.47407/kr2021.2.6.00078
[Borisov V.V. Opasnosti COVID-neiroinfektsii i ee urologicheskikh oslozhnenii, vozmozhnye puti preodoleniia (klinicheskaia lektsiia). Klinicheskii razbor v obshchei meditsine. 2021; 6: 35–41. DOI: 10.47407/kr2021.2.6.00078 (in Russian).]
45. Трухан Д.И., Чуянова Ю.С., Макушин Д.Г. Проблема недержания мочи сквозь призму коморбидности. Клинический разбор в общей медицине. 2021; 9: 11–23. DOI: 10.47407/kr2021.2.9.00103
[Trukhan D.I., Chuianova Iu.S., Makushin D.G. Problema nederzhaniia mochi skvoz' prizmu komorbidnosti. Klinicheskii razbor v obshchei meditsine. 2021; 9: 11–23. DOI: 10.47407/kr2021.2.9.00103 (in Russian).]
46. Silva AB, Freschi G, Carrera RV et al. COVID-19 pandemic impact on clinical outcomes of patients with obstructive pyelonephritis. Int Urol Nephrol 2021; 53 (4): 627–33. DOI: 10.1007/s11255-020-02708-3
47. Borgmann H, Struck JP, Mattigk A et al. Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology. Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology. Urol Int 2021; 105 (3–4): 199–205. DOI: 10.1159/000513458
48. Krol BC, Hemal AK, Fenu EM et al. A rare case of emphysematous pyelonephritis caused by Candida parapsilosis and Finegoldia magna complicated by medical care avoidance. CEN Case Rep 2021; 10 (1): 111–4. DOI: 10.1007/s13730-020-00531-4
49. Cao BL, Brewer O, Cross AR. Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. BMJ Case Rep 2022; 15 (2): e245779. DOI: 10.1136/bcr-2021-245779
50. Djafari AA, Hojjati SA, Rahnama H et al. First report of concurrent mixed germs induced destructive emphysematous pyelonephritis and emphysematous endophthalmitis in the patient with COVID-19. Urol Case Rep 2022; 40: 101908. DOI: 10.1016/j.eucr.2021.101908
51. Boukhannous I, El Moudane A, Chennoufi M et al. Coexistence of Emphysematous Pyelonephritis and Cystitis in a Patient with COVID-19 Complicated with Spontaneous Pneumomediastinum. Coexistence of Emphysematous Pyelonephritis and Cystitis in a Patient with COVID-19 Complicated with Spontaneous Pneumomediastinum. Case Rep Infect Dis 2021; 2021: 3115644. DOI: 10.1155/2021/3115644
52. Castellani D, Ragonese M, Di Rosa M et al. An Italian multicenter analysis of emergency admissions and treatment of upper tract urolithiasis during the lockdown and reopening phases of the COVID-19 pandemic: Are we ready for a second wave of the outbreak? Int J Urol 2021; 28 (9): 950–4. DOI: 10.1111/iju.14612
53. Nourian A, Uppaluri C, Chen M et al. Comparison of Management and Outcomes of Symptomatic Urolithiasis during the COVID-19 Pandemic to a Comparative Cohort. Urology 2022: S0090-4295(22) 00064-4. DOI: 10.1016/j.urology.2022.01.019
54. Anderson S, McNicholas D, Murphy C et al. The impact of COVID-19 on acute urinary stone presentations: a single-centre experience. Ir J Med Sci 2022; 191 (1): 45–9. DOI: 10.1007/s11845-021-02562-x
55. Abdel Raheem A, Alowidah I, Soliman M, et al. Urolithiasis treatment options during COVID-19 pandemic: review of current recommendations and triage systems. Afr J Urol 2020; 26 (1): 75. DOI: 10.1186/s12301-020-00085-y
56. Cepeda M, Budía A, Pérez-Fentes D et al. Strategies and recommendations for urolithiasis treatment and follow-up in COVID-19 pandemia. Arch Esp Urol 2020; 73 (5): 438–46. https://pubmed. ncbi.nlm.nih.gov/32538815/
57. Heijkoop B, Galiabovitch E, York N, Webb D. Consensus of multiple national guidelines: agreed strategies for initial stone management during COVID-19. World J Urol 2021; 39 (9): 3161–74. DOI: 10.1007/ s00345-020-03491-7
58. Scotland K, Tailly T, Chew BH et al. Consensus Statement on Urinary Stone Treatment During A Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative. J Endourol 2022. DOI: 10.1089/end.2021.0477
59. Demirdogen SO, Cinislioglu AE, Cinislioglu N et al. Treatment management of COVID-19 positive patients with renal colic secondary to distal ureteral stone. Int J Clin Pract 2021; 75 (5): e13976. DOI: 10.1111/ijcp.13976
60. Moran SM, Barbour S, Dipchand C et al.; CSN COVID-19 Rapid Response Team. Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. Can J Kidney Health Dis 2020; 7: 2054358120968955. DOI: 10.1177/205435 8120968955
61. May RM, Cassol C, Hannoudi A et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int 2021; 100 (6): 1303–15. DOI: 10.1016/j.kint.2021.07.015
62. Waldman M, Soler MJ, García-Carro C et al. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney Int 2021; 99 (1): 227–37. DOI: 10.1016/j.kint.2020.10.032
63. Wu HHL, Shenoy M, Kalra PA, Chinnadurai R. Intrinsic Kidney Pathology Following COVID-19 Infection in Children and Adolescents: A Systematic Review. Children (Basel) 2021; 9 (1): 3. DOI: 10.3390/children9010003
64. Shieh M, Giannini JA, Combs SA et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits triggered by COVID-19: a case report. CEN Case Rep 2022: 1–6. DOI: 10.1007/s13730-022-00687-1
65. Basiratnia M, Derakhshan D, Yeganeh BS, Derakhshan A. Acute necrotizing glomerulonephritis associated with COVID-19 infection: report of two pediatric cases. Pediatr Nephrol 2021; 36 (4): 1019–23. DOI: 10.1007/s00467-021-04944-w
66. Izci Duran T, Turkmen E, Dilek M et al. ANCA-associated vasculitis after COVID-19. Rheumatol Int 2021; 41 (8): 1523–9. DOI: 10.1007/s00296-021-04914-3
67. Uppal NN, Kello N, Shah HH et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int Rep 2020; 5 (11): 2079–83. DOI: 10.1016/j.ekir.2020.08.012
68. Sethi S, D'Costa MR, Hermann SM et al. Immune-Complex Glomerulonephritis After COVID-19 Infection. Kidney Int Rep 2021; 6 (4): 1170–3. DOI: 10.1016/j.ekir.2021.02.002
69. Guo W, Tan PH, Baikunje S. Membranous nephropathy in a patient with COVID-19 infection. J Nephrol 2022; 35 (1): 351–5. DOI: 10.1007/s40620-021-01165-0
70. Yasri S, Wiwanitkit V. COVID-19-induced de novo nephritic syndrome.Rev Assoc Med Bras (1992) 2021; 67 (1): 6. DOI: 10.1590/ 1806-9282.67.01.20200982
71. Sakthiswary R, Chuah HY, Chiang KS et al. COVID-19 in systemic lupus erythematosus: A pooled analysis and systematic review of case reports and series. Lupus 2021; 30 (12): 1946–54. DOI: 10.1177/09612033211045057
72. Morello W, Vianello FA, Proverbio E et al. COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area. Pediatr Nephrol 2021: 1–8. DOI: 10.1007/s00467-021-05330-2
73. Chan ATP, Tang SCW. De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know? Nephrology (Carlton) 2022; 27 (1): 5–6. DOI: 10.1111/nep.14013
74. Tan HZ, Tan RY, Choo JCJ et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int 2021; 100 (2): 469–71. DOI: 10.1016/j.kint.2021.05.009
75. Li NL, Coates PT, Rovin BH. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int 2021; 100 (5): 959–65. DOI: 10.1016/j.kint.2021.09.002
76. Klomjit N, Alexander MP, Fervenza FC et al. COVID-19 Vaccination and Glomerulonephritis. Kidney Int Rep 2021; 6 (12): 2969–78. DOI: 10.1016/j.ekir.2021.09.008
77. Schaubschlager T, Rajora N, Diep S et al. De novo or recurrent glomerulonephritis and acute tubulointerstitial nephritis after COVID-19 vaccination: A report of six cases from a single center. Clin Nephrol 2022. DOI: 10.5414/CN110794
78. Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int 2021; 100 (1): 238. DOI: 10.1016/j.kint.2021.04.024
79. Plasse R, Nee R, Gao S, Olson S. Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination. Kidney Int 2021; 100 (4): 944–5. DOI: 10.1016/j.kint.2021.07.020
80. Hanna C, Herrera Hernandez LP et al. IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int 202; 100 (3): 705–6. DOI: 10.1016/j.kint.2021.06.032
81. Lim CC, Choo J, Tan CS. COVID-19 Vaccination in Immunoglobulin A Nephropathy. Am J Kidney Dis 2021; 78 (4): 617. DOI: 10.1053/ j.ajkd.2021.07.001
82. Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int 2021; 100 (2): 473–4. DOI: 10.1016/j.kint.2021.05.017
83. Dube GK, Benvenuto LJ, Batal I. Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine. Kidney Int Rep 2021; 6 (12): 3087–9. DOI: 10.1016/j.ekir.2021.08.012
84. Hakroush S, Tampe B. Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination. Front Immunol 2021; 12: 762006. DOI: 10.3389/fimmu.2021. 762006
85. Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021; 78 (4): 611–3. DOI: 10.1053/j.ajkd.2021.06.016
86. Roy S, Kunaparaju S, Koduri NM et al. COVID-19 and APOL-1 High-Risk Genotype-Associated Collapsing Glomerulonephritis. Case Rep Nephrol 2021; 2021: 3737751. DOI: 10.1155/2021/3737751
87. Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report Am J Kidney Dis 2021; 78 (4): 607–10. DOI: 10.1053/j.ajkd.2021.06.008
Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-01-2022/novaya_koronavirusnaya_infektsiya_covid_19_i_zabolevaniya_patologicheskie_sostoyaniya_pochek_i_moche/
[Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii Minzdrava Rossii (15-ia versiia ot 22.02.2022). Moscow, 2022. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/VMR_COVID-19_V15.pdf (in Russian).]
2. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9 (1):727–32. DOI: 10.1080/22221751.2020.1746199
3. Zou X, Chen K, Zou J et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020; 14 (2): 185–92. DOI: 10.1007/ s11684-020-0754-0
4. Wang M, Xiong H, Chen H et al. Renal Injury by SARS-CoV-2 Infection: A Systematic Review. Kidney Dis (Basel). 2021 Mar; 7 (2): 100–10. DOI: 10.1159/000512683
5. Томилина Н.А., Фролова Н.Ф., Артюхина Л.Ю. и др. COVID-19: связь с патологией почек. Обзор литературы. Нефрология и диализ. 2021; 2: 147–59. https://www.elibrary.ru/item.asp?id= 46215426
[Tomilina N.A., Frolova N.F., Artiukhina L.Iu. et al. COVID-19: sviaz' s patologiei pochek. Obzor literatury. Nefrologiia i dializ. 2021; 2: 147–59. https://www.elibrary.ru/item.asp?id=46215426 (in Rus-sian).]
6. Павлов В.Н., Тарасенко А.И., Папоян А.О. и др. Острое повреждение почек в патогенезе коронавирусной инфекции. Урология. 2021; 2: 116–9. DOI: 10.18565/urology.2021.2.116-119
[Pavlov V.N., Tarasenko A.I., Papoian A.O. et al. Ostroe povrezhdenie pochek v patogeneze koronavirusnoi infektsii. Urologiia. 2021; 2: 116–9. DOI: 10.18565/urology.2021.2.116-119 (in Russian).]
7. Демяшкин Г.А., Мингазов А.М., Каприна Е.А. и др. Молекулярно-генетические изменения ткани почек пациентов с COVID-19. Исследования и практика в медицине. 2021; 8 (3): 45–51. DOI: 10.17709/2410-1893-2021-8-3-4
[Demiashkin G.A., Mingazov A.M., Kaprina E.A. et al. Molekuliarno-geneticheskie izmeneniia tkani pochek patsientov s COVID-19. Issledovaniia i praktika v meditsine. 2021; 8 (3): 45–51. DOI: 10.17709/2410-1893-2021-8-3-4 (in Russian).]
8. Ouyang L, Gong Y, Zhu Y, Gong J. Association of acute kidney injury with the severity and mortality of SARS-CoV-2 infection: A meta-analysis. Am J Emerg Med 2021; 43: 149–57. DOI: 10.1016/j.ajem.2020 08.089
9. Острое повреждение почек (ОПП). Клинические рекомендации. М., 2020. https://rusnephrology.org/wp-content/uploads/2020/12/ AKI_final.pdf
[Ostroe povrezhdenie pochek (OPP). Klinicheskie rekomendatsii. Moscow, 2020. https://rusnephrology.org/wp-content/uploads/ 2020/12/AKI_final.pdf (in Russian).]
10. Pecly IMD, Azevedo RB, Muxfeldt ES et al. A review of Covid-19 and acute kidney injury: from pathophysiology to clinical results. J Bras Nefrol 2021; 43 (4): 551–71. DOI: 10.1590/2175-8239-JBN-2020-0204
11. Yang XH, Sun RH, Chen DC. Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored. Zhonghua Yi Xue Za Zhi 2020; 100 (16): 1205–8. DOI: 10.3760/cma.j.cn112137-20200229-00520
12. Ng JH, Bijol V, Sparks MA et al. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis 2020; 27 (5): 365–76. DOI: 10.1053/j.ackd.2020.09.003
13. Menon T, Sharma R, Kataria S et al. The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. Cureus 2021; 13 (3): e13894. DOI: 10.7759/cureus.13894
14. Chan KW, Yu KY, Lee PW et al. Global REnal Involvement of CORonavirus Disease 2019 (RECORD): A Systematic Review and Meta-Analysis of Incidence, Risk Factors, and Clinical Outcomes. Front Med (Lausanne) 2021; 8: 678200. DOI: 10.3389/fmed.2021.678200
15. Oliveira CB, Lima CAD, Vajgel G et al. High burden of acute kidney injury in COVID-19 pandemic: systematic review and meta-analysis. J Clin Pathol 2021; 74 (12): 796–803. DOI: 10.1136/jclinpath-2020-207023
16. Alenezi FK, Almeshari MA, Mahida R et al. Incidence and risk factors of acute kidney injury in COVID-19 patients with and without acute respiratory distress syndrome (ARDS) during the first wave of COVID-19: a systematic review and Meta-Analysis. Ren Fail 2021; 43 (1): 1621–33. DOI: 10.1080/0886022X.2021.2011747
17. Raina R, Mahajan ZA, Vasistha P et al. Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review. Blood Purif 2021: 1–14. DOI: 10.1159/000514940
18. Santos RPD, Lordani TVA, Peres LAB, Carvalho ARDS. Occurrence of acute kidney injury in adult patients hospitalized with COVID-19: A systematic review and meta-analysis. Nefrologia (Engl Ed) 2021. DOI: 10.1016/j.nefro.2021.09.002
19. Cai X, Wu G, Zhang J, Yang L. Risk Factors for Acute Kidney Injury in Adult Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021; 8: 719472. DOI: 10.3389/fmed.2021.719472
20. Чеботарева Н.В., Бернс С.А., Мясников А.Л. и др. Частота, факторы риска и прогностическое значение острого повреждения почек у госпитализированных больных c COVID-19: ретроспективное когортное исследование. Клиническая фармакология и терапия. 2021; 1: 30–5. DOI: 10.32756/0869-5490-2021-1-30-35
[Chebotareva N.V., Berns S.A., Miasnikov A.L. et al. Chastota, faktory riska i prognosticheskoe znachenie ostrogo povrezhdeniia pochek u gospitalizirovannykh bol'nykh c COVID-19: retrospektivnoe kogortnoe issledovanie. Klinicheskaia farmakologiia i terapiia. 2021; 1: 30–5. DOI: 10.32756/0869-5490-2021-1-30-35 (in Russian).]
21. Chan VW, Chiu PK, Yee CH et al. A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions. World J Urol 2021; 39 (9): 3127–38. DOI: 10.1007/s00345-020-03246-4
22. Громова Г.Г., Верижникова Л.Н., Жбанова Н.В. и др. Повреждение почек при новой коронавирусной инфекции COVID-19. Клиническая нефрология. 2021; 3: 17–22. DOI: 10.18565/nephrology.2021.3.17-22
[Gromova G.G., Verizhnikova L.N., Zhbanova N.V. et al. Povrezhdenie pochek pri novoi koronavirusnoi infektsii COVID-19. Klinicheskaia nefrologiia. 2021; 3: 17–22. DOI: 10.18565/nephrology.2021.3.17-22 (in Russian).]
23. Cai R, Zhang J, Zhu Y et al. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. Int Urol Nephrol 2021; 53 (8): 1623–9. DOI: 10.1007/s11255-020-02740-3
24. Menon T, Gandhi SAQ, Tariq W et al. Impact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis. Cureus 2021; 13 (4): e14279. DOI: 10.7759/cureus.14279
25. Lin YC, Lai TS, Lin SL et al. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021; 12: 2040622321998860. DOI: 10.1177/2040622321998860
26. Chung EYM, Palmer SC, Natale P et al. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis 2021; 78 (6): 804–15. DOI: 10.1053/j.ajkd. 2021.07.003
27. Singh J, Malik P, Patel N et al. Kidney disease and COVID-19 disease severity-systematic review and meta-analysis. Clin Exp Med 2022; 22 (1): 125–35. DOI: 10.1007/s10238-021-00715-x
28. Nopsopon T, Kittrakulrat J, Takkavatakarn K et al. Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis. PLoS Negl Trop Dis 2021; 15 (6): e0009156. DOI: 10.1371/journal.pntd.0009156
29. Wang F, Ao G, Wang Y et al. Risk factors for mortality in hemodialysis patients with COVID-19: a systematic review and meta-analysis. Ren Fail 2021; 43 (1): 1394–407. DOI: 10.1080/0886022X. 2021.1986408
30. Сивков А.В., Корякин А.В., Синягин А.А. и др. Мочеполовая система и COVID-19: некоторые аспекты. Экспериментальная и клиническая урология. 2020; 2: 18–23. DOI: 10.29188/2222-8543-2020-12-2-18-23
[Sivkov A.V., Koriakin A.V., Siniagin A.A. et al. Mochepolovaia sistema i COVID-19: nekotorye aspekty. Eksperimental'naia i klinicheskaia urologiia. 2020; 2: 18–23. DOI: 10.29188/2222-8543-2020-12-2-18-23 (in Russian).]
31. Heldwein FL, Loeb S, Wroclawski ML et al. A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic. Eur Urol Focus 2020; 6 (5): 1070–85. DOI: 10.1016/j.euf.2020.05.020
32. Лаухтина Е.А., Шпикина А.Д., Тараткин М.С. и др. Обзор рекомендаций европейской ассоциации урологов по ведению урологических пациентов в период пандемии COVID-19. Вопросы урологии и андрологии. 2020; 1: 52–9. DOI: 10.20953/2307-6631-2020-1-52-59
[Laukhtina E.A., Shpikina A.D., Taratkin M.S. et al. Obzor rekomendatsii evropeiskoi assotsiatsii urologov po vedeniiu urologicheskikh patsientov v period pandemii COVID-19. Voprosy urologii i andrologii. 2020; 1: 52–9. DOI: 10.20953/2307-6631-2020-1-52-59 (in Russian).]
33. Малхасян В.А., Касян Г.Р., Ходырева Л.А. и др. Оказание стационарной помощи пациентам урологического профиля в условиях пандемии коронавирусной инфекции COVID-19. Экспериментальная и клиническая урология. 2020; 1: 4–11. DOI: 10.29188/2222-8543-2020-12-1-4-11
[Malkhasian V.A., Kasian G.R., Khodyreva L.A. et al. Okazanie statsionarnoi pomoshchi patsientam urologicheskogo profilia v usloviiakh pandemii koronavirusnoi infektsii COVID-19. Eksperimental'naia i klinicheskaia urologiia. 2020; 1: 4–11. DOI: 10.29188/2222-8543-2020-12-1-4-11 (in Russian).]
34. Mumm JN, Osterman A, Ruzicka M et al. Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis? Eur Urol 2020; 78 (4): 624–8. DOI: 10.1016/j.eururo.2020.05.013
35. Lamb LE, Dhar N, Timar R et al. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Med Hypotheses 2020; 145: 110375. DOI: 10.1016/j.mehy. 2020.110375
36. Dhar N, Dhar S, Timar R et al. De Novo Urinary Symptoms Associated With COVID-19: COVID-19-Associated Cystitis. J Clin Med Res 2020; 12 (10): 681–2. DOI: 10.14740/jocmr4294
37. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных синдромов и симптомов при заболеваниях почек и мочевых путей. М.: Практическая медицина, 2019. https://www. elibrary.ru/item.asp?id=47503998
[Trukhan D.I., Filimonov S.N. Differentsial'nyi diagnoz osnovnykh sindromov i simptomov pri zabolevaniiakh pochek i mochevykh putei. Moscow: Prakticheskaia meditsina, 2019. https://www.elibrary. ru/item.asp?id=47503998 (in Russian).]
38. Трухан Д.И., Юренев Г.Л., Макушин Д.Г., Чусова Н.А. Симптомы нижних мочевых путей: дифференциальный диагноз на этапе оказания первичной медико-санитарной помощи. Справочник поликлинического врача. 2019; 3: 23–8. https://www.elibrary.ru/ item.asp?id=41351801
[Trukhan D.I., Iurenev G.L., Makushin D.G., Chusova N.A. Simptomy nizhnikh mochevykh putei: differentsial'nyi diagnoz na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi. Spravochnik poliklinicheskogo vracha. 2019; 3: 23–8. https://www.elibrary.ru/ item.asp?id=41351801 (in Russian).]
39. Kaya Y, Kaya C, Kartal T et al. Could LUTS be early symptoms of COVID-19. Int J Clin Pract 2021; 75 (3): e13850. DOI: 10.1111/ ijcp.13850
40. Bernikov AN, Kupriyanov AA, Stroganov RV et al. Lower urinary tract symptoms and COVID-19. Urologiia 2021; 5: 78–83. https://pubmed.ncbi.nlm.nih.gov/35165599/
41. Lamb LE, Timar R, Wills M et al. Long COVID and COVID-19-associated cystitis (CAC). Int Urol Nephrol 2022; 54 (1): 17–21. DOI: 10.1007/s11255-021-03030-2
42. Pourfridoni M, Pajokh M, Seyedi F. Bladder and bowel incontinence in COVID-19. J Med Virol 2021; 93 (5): 2609–10. DOI: 10.1002/ jmv.26849
43. Araujo MP, Brito LGO, Pochini AC et al. Prevalence of Urinary Incontinence in CrossFit Practitioners before and during the COVID-19 Quarantine and its Relationship with Training Level: An Observational Study. Rev Bras Ginecol Obstet 2021; 43 (11): 847–52. DOI: 10.1055/s-0041-1739463
44. Борисов В.В. Опасности COVID-нейроинфекции и ее урологических осложнений, возможные пути преодоления (клиническая лекция). Клинический разбор в общей медицине. 2021; 6: 35–41. DOI: 10.47407/kr2021.2.6.00078
[Borisov V.V. Opasnosti COVID-neiroinfektsii i ee urologicheskikh oslozhnenii, vozmozhnye puti preodoleniia (klinicheskaia lektsiia). Klinicheskii razbor v obshchei meditsine. 2021; 6: 35–41. DOI: 10.47407/kr2021.2.6.00078 (in Russian).]
45. Трухан Д.И., Чуянова Ю.С., Макушин Д.Г. Проблема недержания мочи сквозь призму коморбидности. Клинический разбор в общей медицине. 2021; 9: 11–23. DOI: 10.47407/kr2021.2.9.00103
[Trukhan D.I., Chuianova Iu.S., Makushin D.G. Problema nederzhaniia mochi skvoz' prizmu komorbidnosti. Klinicheskii razbor v obshchei meditsine. 2021; 9: 11–23. DOI: 10.47407/kr2021.2.9.00103 (in Russian).]
46. Silva AB, Freschi G, Carrera RV et al. COVID-19 pandemic impact on clinical outcomes of patients with obstructive pyelonephritis. Int Urol Nephrol 2021; 53 (4): 627–33. DOI: 10.1007/s11255-020-02708-3
47. Borgmann H, Struck JP, Mattigk A et al. Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology. Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology. Urol Int 2021; 105 (3–4): 199–205. DOI: 10.1159/000513458
48. Krol BC, Hemal AK, Fenu EM et al. A rare case of emphysematous pyelonephritis caused by Candida parapsilosis and Finegoldia magna complicated by medical care avoidance. CEN Case Rep 2021; 10 (1): 111–4. DOI: 10.1007/s13730-020-00531-4
49. Cao BL, Brewer O, Cross AR. Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. BMJ Case Rep 2022; 15 (2): e245779. DOI: 10.1136/bcr-2021-245779
50. Djafari AA, Hojjati SA, Rahnama H et al. First report of concurrent mixed germs induced destructive emphysematous pyelonephritis and emphysematous endophthalmitis in the patient with COVID-19. Urol Case Rep 2022; 40: 101908. DOI: 10.1016/j.eucr.2021.101908
51. Boukhannous I, El Moudane A, Chennoufi M et al. Coexistence of Emphysematous Pyelonephritis and Cystitis in a Patient with COVID-19 Complicated with Spontaneous Pneumomediastinum. Coexistence of Emphysematous Pyelonephritis and Cystitis in a Patient with COVID-19 Complicated with Spontaneous Pneumomediastinum. Case Rep Infect Dis 2021; 2021: 3115644. DOI: 10.1155/2021/3115644
52. Castellani D, Ragonese M, Di Rosa M et al. An Italian multicenter analysis of emergency admissions and treatment of upper tract urolithiasis during the lockdown and reopening phases of the COVID-19 pandemic: Are we ready for a second wave of the outbreak? Int J Urol 2021; 28 (9): 950–4. DOI: 10.1111/iju.14612
53. Nourian A, Uppaluri C, Chen M et al. Comparison of Management and Outcomes of Symptomatic Urolithiasis during the COVID-19 Pandemic to a Comparative Cohort. Urology 2022: S0090-4295(22) 00064-4. DOI: 10.1016/j.urology.2022.01.019
54. Anderson S, McNicholas D, Murphy C et al. The impact of COVID-19 on acute urinary stone presentations: a single-centre experience. Ir J Med Sci 2022; 191 (1): 45–9. DOI: 10.1007/s11845-021-02562-x
55. Abdel Raheem A, Alowidah I, Soliman M, et al. Urolithiasis treatment options during COVID-19 pandemic: review of current recommendations and triage systems. Afr J Urol 2020; 26 (1): 75. DOI: 10.1186/s12301-020-00085-y
56. Cepeda M, Budía A, Pérez-Fentes D et al. Strategies and recommendations for urolithiasis treatment and follow-up in COVID-19 pandemia. Arch Esp Urol 2020; 73 (5): 438–46. https://pubmed. ncbi.nlm.nih.gov/32538815/
57. Heijkoop B, Galiabovitch E, York N, Webb D. Consensus of multiple national guidelines: agreed strategies for initial stone management during COVID-19. World J Urol 2021; 39 (9): 3161–74. DOI: 10.1007/ s00345-020-03491-7
58. Scotland K, Tailly T, Chew BH et al. Consensus Statement on Urinary Stone Treatment During A Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative. J Endourol 2022. DOI: 10.1089/end.2021.0477
59. Demirdogen SO, Cinislioglu AE, Cinislioglu N et al. Treatment management of COVID-19 positive patients with renal colic secondary to distal ureteral stone. Int J Clin Pract 2021; 75 (5): e13976. DOI: 10.1111/ijcp.13976
60. Moran SM, Barbour S, Dipchand C et al.; CSN COVID-19 Rapid Response Team. Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. Can J Kidney Health Dis 2020; 7: 2054358120968955. DOI: 10.1177/205435 8120968955
61. May RM, Cassol C, Hannoudi A et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int 2021; 100 (6): 1303–15. DOI: 10.1016/j.kint.2021.07.015
62. Waldman M, Soler MJ, García-Carro C et al. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney Int 2021; 99 (1): 227–37. DOI: 10.1016/j.kint.2020.10.032
63. Wu HHL, Shenoy M, Kalra PA, Chinnadurai R. Intrinsic Kidney Pathology Following COVID-19 Infection in Children and Adolescents: A Systematic Review. Children (Basel) 2021; 9 (1): 3. DOI: 10.3390/children9010003
64. Shieh M, Giannini JA, Combs SA et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits triggered by COVID-19: a case report. CEN Case Rep 2022: 1–6. DOI: 10.1007/s13730-022-00687-1
65. Basiratnia M, Derakhshan D, Yeganeh BS, Derakhshan A. Acute necrotizing glomerulonephritis associated with COVID-19 infection: report of two pediatric cases. Pediatr Nephrol 2021; 36 (4): 1019–23. DOI: 10.1007/s00467-021-04944-w
66. Izci Duran T, Turkmen E, Dilek M et al. ANCA-associated vasculitis after COVID-19. Rheumatol Int 2021; 41 (8): 1523–9. DOI: 10.1007/s00296-021-04914-3
67. Uppal NN, Kello N, Shah HH et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int Rep 2020; 5 (11): 2079–83. DOI: 10.1016/j.ekir.2020.08.012
68. Sethi S, D'Costa MR, Hermann SM et al. Immune-Complex Glomerulonephritis After COVID-19 Infection. Kidney Int Rep 2021; 6 (4): 1170–3. DOI: 10.1016/j.ekir.2021.02.002
69. Guo W, Tan PH, Baikunje S. Membranous nephropathy in a patient with COVID-19 infection. J Nephrol 2022; 35 (1): 351–5. DOI: 10.1007/s40620-021-01165-0
70. Yasri S, Wiwanitkit V. COVID-19-induced de novo nephritic syndrome.Rev Assoc Med Bras (1992) 2021; 67 (1): 6. DOI: 10.1590/ 1806-9282.67.01.20200982
71. Sakthiswary R, Chuah HY, Chiang KS et al. COVID-19 in systemic lupus erythematosus: A pooled analysis and systematic review of case reports and series. Lupus 2021; 30 (12): 1946–54. DOI: 10.1177/09612033211045057
72. Morello W, Vianello FA, Proverbio E et al. COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area. Pediatr Nephrol 2021: 1–8. DOI: 10.1007/s00467-021-05330-2
73. Chan ATP, Tang SCW. De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know? Nephrology (Carlton) 2022; 27 (1): 5–6. DOI: 10.1111/nep.14013
74. Tan HZ, Tan RY, Choo JCJ et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int 2021; 100 (2): 469–71. DOI: 10.1016/j.kint.2021.05.009
75. Li NL, Coates PT, Rovin BH. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int 2021; 100 (5): 959–65. DOI: 10.1016/j.kint.2021.09.002
76. Klomjit N, Alexander MP, Fervenza FC et al. COVID-19 Vaccination and Glomerulonephritis. Kidney Int Rep 2021; 6 (12): 2969–78. DOI: 10.1016/j.ekir.2021.09.008
77. Schaubschlager T, Rajora N, Diep S et al. De novo or recurrent glomerulonephritis and acute tubulointerstitial nephritis after COVID-19 vaccination: A report of six cases from a single center. Clin Nephrol 2022. DOI: 10.5414/CN110794
78. Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int 2021; 100 (1): 238. DOI: 10.1016/j.kint.2021.04.024
79. Plasse R, Nee R, Gao S, Olson S. Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination. Kidney Int 2021; 100 (4): 944–5. DOI: 10.1016/j.kint.2021.07.020
80. Hanna C, Herrera Hernandez LP et al. IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int 202; 100 (3): 705–6. DOI: 10.1016/j.kint.2021.06.032
81. Lim CC, Choo J, Tan CS. COVID-19 Vaccination in Immunoglobulin A Nephropathy. Am J Kidney Dis 2021; 78 (4): 617. DOI: 10.1053/ j.ajkd.2021.07.001
82. Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int 2021; 100 (2): 473–4. DOI: 10.1016/j.kint.2021.05.017
83. Dube GK, Benvenuto LJ, Batal I. Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine. Kidney Int Rep 2021; 6 (12): 3087–9. DOI: 10.1016/j.ekir.2021.08.012
84. Hakroush S, Tampe B. Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination. Front Immunol 2021; 12: 762006. DOI: 10.3389/fimmu.2021. 762006
85. Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021; 78 (4): 611–3. DOI: 10.1053/j.ajkd.2021.06.016
86. Roy S, Kunaparaju S, Koduri NM et al. COVID-19 and APOL-1 High-Risk Genotype-Associated Collapsing Glomerulonephritis. Case Rep Nephrol 2021; 2021: 3737751. DOI: 10.1155/2021/3737751
87. Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report Am J Kidney Dis 2021; 78 (4): 607–10. DOI: 10.1053/j.ajkd.2021.06.008
Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-01-2022/novaya_koronavirusnaya_infektsiya_covid_19_i_zabolevaniya_patologicheskie_sostoyaniya_pochek_i_moche/
For citation:Trukhan D.I. New coronavirus infection (COVID-19) and kidney-urinary tract diseases / pathological conditions. Clinical review for general practice. 2022; 1: 6–15. DOI: 10.47407/kr2022.3.1.00111
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.